Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alder BioPharmaceuticals Inc.

www.alderbio.com

Latest From Alder BioPharmaceuticals Inc.

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis

Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.

Clinical Trials Neurology

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies

Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Approvals

Novartis Gets NICE Headache From Aimovig Knockback

The cost-effectiveness watchdog is worried about the cost of Novartis's once-monthly first-in-class migraine drug and is not convinced it is more effective than Allergan’s Botox, which can require up to 40 injections into the head and neck.

Reimbursement Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alder BioPharmaceuticals Inc.
  • Senior Management
  • Robert W Azelby, CEO
    Carlos Campoy, CFO
    Mark J Litton, PhD, CBO
    John A Latham, PhD, CSO
    Elisabeth A Sandoval, Chief Commercial Officer & EVP, Corp. Strat.
    Erin Lavelle, COO
  • Contact Info
  • Alder BioPharmaceuticals Inc.
    Phone: (425) 205-2900
    11804 North Creek Pkwy. S.
    Bothell, WA 98011
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register